Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
175.71B
Market cap175.71B
Price-Earnings ratio
10.24
Price-Earnings ratio10.24
Dividend yield
3.02%
Dividend yield3.02%
Average volume
14.57M
Average volume14.57M
High today
$40.57
High today$40.57
Low today
$39.46
Low today$39.46
Open price
$40.15
Open price$40.15
Volume
7.74M
Volume7.74M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

TipRanks 19m
Novo Nordisk put volume heavy and directionally bearish

Bearish flow noted in Novo Nordisk (NVO) with 41,430 puts trading, or 4x expected. Most active are Dec-26 35 puts and Dec-27 40 puts, with total volume in those...

The Motley Fool 20h
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

The global demand for next-generation metabolic treatments has sparked a fierce competition, forcing retail investors to decide between Eli Lilly & Co. (LLY -1....

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Benzinga 1d
Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based therapies support bone health during weigh...

Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops

Analyst ratings

50%

of 8 ratings
Buy
25%
Hold
50%
Sell
25%

More NVO News

The Motley Fool 1d
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue

Johnson & Johnson: A Steady Revenue Uptrend Johnson & Johnson (JNJ -1.12%) primarily generates revenue by developing and selling pharmaceutical treatments and m...

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
TipRanks 2d
Novo Nordisk presents new research that includes cagrilintide study

The company states: “Novo Nordisk (NVO) presented new research at ObesityWeek 2026 exploring biomarkers related to bone health across multiple investigational a...

Zacks 2d
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema

Novo (NVO Quick QuoteNVO - Free Report) announced that the European Commission (EC) has granted marketing authorization for Frehemgo (denecimig) for routi...

NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Benzinga 2d
Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision

Novo Nordisk (NYSE:NVO) presented trial and real-world data at ObesityWeek 2026 showing strong weight loss for investigational CagriSema and reduced food noise...

Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision
The Wall Street Journal 2d
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval

Novo Nordisk published positive trial results for its next-generation obesity drug CagriSema. Mads Claus Rasmussen / Ritzau Scanpix / Agence France-Presse / Get...

Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
The Motley Fool 3d
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027

Eli Lilly (LLY +1.26%) and Novo Nordisk (NVO +2.41%) are leading the fast-growing market for weight loss drugs, but they have had very different fortunes over t...

Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
TipRanks 3d
Novo Nordisk announces results from two post hoc analyses of phase 3 Redefine 1

Novo Nordisk (NVO) announced results from two post hoc analyses of the phase 3 Redefine 1 trial of investigational CagriSema 2.4 mg / 2.4 mg, a fixed-dose combi...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.